Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other solid neoplasm 1Gynecologic 1Gastrointestinal 1

Conditions

Sarcoma 1Ovarian Neoplasms 1Neoplasms 1Mesothelioma 1Colorectal Neoplasms 1

Interventions

pembrolizumab 4Cisplatin 3Carboplatin 3budigalimab 2Pemetrexed 2Paclitaxel 2Immunotherapy 2Etoposide 2Drug Therapy 2Docetaxel 2Cyclophosphamide 2venetoclax 1trametinib 1spartalizumab 1sargramostim 1rovalpituzumab tesirine 1ribociclib 1poly ICLC 1fludarabine 1enzalutamide 1entinostat 1belinostat 1UV1 vaccine 1Tomography, Optical Coherence 1Thrombopoietin 1Sunitinib 1Sirolimus 1Quality of Life 1Polymerase Chain Reaction 1Patient Reported Outcome Measures 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × OSI 930 × Other solid neoplasm × Clear all
NCT00603356 2011-09-27

Phase I Study of OSI-930 and Erlotinib in Cancer Tumors

Astellas Pharma Inc

Phase 1 Completed
60 enrolled
GastrointestinalGynecologicOther solid neoplasmSarcomaThoracic

Mesothelioma, Neoplasms, Ovarian Neoplasms, Sarcoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡